Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 37.8259
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 899558538521.0
- FreeCF/Share 10.0576
- PFCF 99.7216
- PE 48.8811
- Debt/Assets 0.3698
- DivYield 0.006
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Which Pharma Stock Stands Taller Right Now: LLY or PFE?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.
Read More
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Read More
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Negative
Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Buy The Dip In LLY Stock?
Published: January 16, 2026 by: Forbes
Sentiment: Positive
Eli Lilly's recent decline of 3.76% following the FDA's delay regarding its oral weight-loss pill Orforglipron signifies a strategic buying chance rather than a matter of concern. Although the stock is trading at a premium valuation, the company's outstanding operational performance, strong financial condition, and encouraging long-term predictions in the obesity treatment field validate the decision to maintain or increase positions for long-term investors.
Read More
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
Read More
MoneyShow's Best Investment Ideas For 2026: Part 4
Published: January 14, 2026 by: Seeking Alpha
Sentiment: Positive
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 3 of this series includes Eli Lilly, Enterprise Products Partners, Expand Energy Corp., Federal Agricultural Mortgage Corp., and GE Vernova, among others.
Read More
Here's Why Eli Lilly (LLY) is a Strong Momentum Stock
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly
Published: January 12, 2026 by: Bloomberg Technology
Sentiment: Positive
Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., in an effort to speed up the use of AI in the pharmaceutical industry. Denny Fish, portfolio manager on the Global Technology and Innovation Team at Janus Henderson Investors, joins Caroline Hyde and Ed Ludlow on “Bloomberg Tech.
Read More
Eli Lilly CFO on $1 billion Nvidia investment
Published: January 12, 2026 by: Bloomberg Markets and Finance
Sentiment: Positive
NVIDIA plans to invest $1 billion over five years in a new laboratory with Eli Lilly and Company, aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Heres what Eli Lilly CFO Lucas Montarce had to say about the partnership.
Read More
Nvidia and Eli Lilly launch Co-Innovation AI Lab to advance drug discovery
Published: January 12, 2026 by: Proactive Investors
Sentiment: Positive
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) and Eli Lilly and Co (NYSE:LLY) have announced the creation of a new AI-focused co-innovation lab aimed at accelerating drug discovery and development. The lab will combine Lilly's expertise in medicine discovery, development, and manufacturing with Nvidia's AI and computing capabilities, the companies announced on Monday.
Read More
Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma's Future
Published: January 12, 2026 by: 24/7 Wall Street
Sentiment: Neutral
One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery.
Read More
Eli Lilly CFO on $1 Billion AI Drug Lab Investment
Published: January 12, 2026 by: Bloomberg Markets and Finance
Sentiment: Positive
Eli Lilly Chief Financial Officer Lucas Montarce says the company's weight-loss pill is on track to be approved in the US as early as the second quarter of this year. He speaks to Katie Greifeld at the JPMorgan Healthcare Conference in San Francisco.
Read More
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Nvidia Partners With Eli Lilly on AI Drug Laboratory
Published: January 12, 2026 by: Bloomberg Markets and Finance
Sentiment: Positive
Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Jessica Nix has more on "Bloomberg Open Interest.
Read More
Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
Published: January 12, 2026 by: Reuters
Sentiment: Positive
Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area over five years which will use Nvidia's newest generation Vera Rubin AI chips, the firms said on Monday.
Read More
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
Published: January 09, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co.
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Lilly's Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
Published: January 08, 2026 by: Reuters
Sentiment: Positive
Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Taltz alone.
Read More
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)
Published: January 08, 2026 by: Newsfile Corp
Sentiment: Neutral
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (NYSE: LLY) for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The investigation concerns whether the Ventyx Board breached its fiduciary duties to shareholders …
Read More
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.
Read More
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
Published: January 06, 2026 by: WSJ
Sentiment: Positive
The more-than-$1 billion deal could come imminently.
Read More
Are You Looking for a Top Momentum Pick? Why Eli Lilly (LLY) is a Great Choice
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Eli Lilly, Nimbus Partner to Develop, License Oral Obesity Treatment
Published: January 06, 2026 by: WSJ
Sentiment: Positive
Eli Lilly and Nimbus Therapeutics have entered into a multiyear collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.
Read More
Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum
Published: January 06, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly (LLY) remains a Strong Buy, driven by robust GLP-1 demand and stellar execution, delivering a 34% total return since initial bullish coverage. LLY's Q3 results showed a 10% revenue and 19% EPS beat, with operating margin expanding from 40% to 48% YoY, and cash from operations surging to $8.8 billion. Flagship products Mounjaro and Zepbound posted 100%+ YoY revenue growth; late-stage pipeline assets like orforglipron and retatrutide reinforce LLY's GLP-1 leadership.
Read More
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Read More
Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?
Published: January 06, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent quarters thanks to its weight loss portfolio.
Read More
3 Reasons Why Lilly (LLY) Is a Great Growth Stock
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.
Read More
3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.
Read More
LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000